Marathon Pharmaceuticals recently published the results of a clinical study that confirmed its ZiNGO (lidocaine hydrochloride monohydrate, 0.5 mg) powder intradermal injection system can significantly decrease venous access pain experienced by pediatric patients.
The results of the study were published in the journal Clinical Therapeutics.
ZiNGO is described by Marathon as "a fast-acting, easy-to-use, sterile, needle-free product that, with the push of a button, delivers a 0.5 mg dose of powdered lidocaine particles into the skin, numbing the site in just one to three minutes."
The medication, which is being used at many major children's hospitals across the nation, was tested using a randomized, double-blind, placebo-controlled study. Data was collected from 535 patients ages 3-18. The test subjects were in outpatient and inpatient settings and were undergoing venipuncture or peripheral venous cannulation procedures as part of their care routines.
"The active system group had signicantly less pain compared with the placebo in all age groups combined," Marathon's report said.
There were some adverse side effects reported, most commonly nausea and vomiting as well as bruising, burning and pain.
"This study confirms that ZiNGO is an easy-to-administer, fast-acting, safe and effective, needle-free topical local anesthetic that can be easily incorporated into the busy health care environment,” William Zempsky, professor of pediatrics at Connecticut Children’s Medical Center and a study author, said. “Because commonly available local anesthetic products can take up to 30 to 60 minutes to work, making incorporation into the busy health care environment difficult, health care providers have had to sacrifice patient comfort when performing the numerous venous access procedures that occur each day. ZiNGO can be a source of needed relief to children and parents.”
